EU schizophrenia guidance highlights unmet needs
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's new guidelines on developing schizophrenia treatments now include recommendations on R&D that targets the condition's traditionally overlooked negative and cognitive symptoms. The guidelines are encouraging because they highlight areas of unmet need, but developmental challenges mean they will not "translate into the launch of marketed products in the mid-term", said Charlotte Mackey, a lead analyst at Datamonitor.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.